Paradigm Biocapital Advisors Gp Llc - Net Worth and Insider Trading

Paradigm Biocapital Advisors Gp Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Paradigm Biocapital Advisors Gp Llc owns 1 companies in total, including Olema Pharmaceuticals inc (OLMA) .

Click here to see the complete history of Paradigm Biocapital Advisors Gp Llc’s form 4 insider trades.

Insider Ownership Summary of Paradigm Biocapital Advisors Gp Llc

Ticker	Comapny	Transaction Date	Type of Owner
OLMA	Olema Pharmaceuticals inc	2023-09-12	10 percent owner

Paradigm Biocapital Advisors Gp Llc Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Paradigm Biocapital Advisors Gp Llc Ownership Network

Ownership Network List of Paradigm Biocapital Advisors Gp Llc

No Data

Ownership Network Relation of Paradigm Biocapital Advisors Gp Llc

Paradigm Biocapital Advisors Gp Llc Owned Company Details

What does Olema Pharmaceuticals inc do?

Who are the key executives at Olema Pharmaceuticals inc?

Paradigm Biocapital Advisors Gp Llc is the 10 percent owner of Olema Pharmaceuticals inc. Other key executives at Olema Pharmaceuticals inc include 10 percent owner Paradigm Biocapital Advisors Lp , director & Chief Technology Officer Cyrus Harmon , and director & President and CEO Sean Bohen .

Olema Pharmaceuticals inc (OLMA) Insider Trades Summary

Over the past 18 months, Paradigm Biocapital Advisors Gp Llc made no insider transaction in Olema Pharmaceuticals inc (OLMA). Other recent insider transactions involving Olema Pharmaceuticals inc (OLMA) include a net sale of 338,181 shares made by Cyrus Harmon , a net sale of 44,370 shares made by David C. Myles , and a net sale of 2,300,000 shares made by Paradigm Biocapital Advisors Lp .

In summary, during the past 3 months, insiders sold 2,430,000 shares of Olema Pharmaceuticals inc (OLMA) in total and bought 0 shares, with a net sale of 2,430,000 shares. During the past 18 months, 4,048,074 shares of Olema Pharmaceuticals inc (OLMA) were sold and 2,255,932 shares were bought by its insiders, resulting in a net sale of 1,792,142 shares.

Olema Pharmaceuticals inc (OLMA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Olema Pharmaceuticals inc Insider Transactions

No Available Data

Paradigm Biocapital Advisors Gp Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Paradigm Biocapital Advisors Gp Llc. You might contact Paradigm Biocapital Advisors Gp Llc via mailing address: 767 Third Avenue, 17th Floor, New York City Ny 10017.

Discussions on Paradigm Biocapital Advisors Gp Llc

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.